Description: C5, Mouse, mAb BB5.1, immuno assay antibody
C5 is synthesised in the liver as a single polypeptide chain and is present in serum in a concentration of 50-80 µm/ml. Before secretion the molecule is glycosylated and secreted into plasma as a 190 kDa glycoprotein consisting of a disulphide linked alpha-chain (111 kDa) and beta-chain (75 kDa). Monoclonal antibody BB5.1 has been shown to precipitate the two chains of C5 from normal mouse serum and inhibited C5-dependent hemolysis in a functional complement test. Furthermore, BB5.1 administration completely inhibits terminal complement activity in murine models for antibody-mediated rejection (AMR) during heart and kidney transplantation. In another mouse model, both pre-treatment as well as intervention with monoclonal antibody BB5.1 attenuates disease development during anti-MPO IgG-induced glomerulonephritis. Blockage of C5 activation by BB5.1 protects against renal ischemia-reperfusion injury by inhibition of late apoptosis and inflammation. In Lupus disease, combination therapy of anti-IL-10/anti-C5 (BB5.1) can both prevent and reduce the effect of the humoral immune response.
|Product type||Monoclonal antibodies|
|Formulation||0.5 mg (100 μg/ml) 0.2 μm filtered protein G purified antibody solution in PBS with a concentration of at least 0.5 mg/ml (exact concentration is indicated on the label).|
|Application||F, FS, IA, IF, IP, P|
|Application Notes||FS: ex vivo: 50 µg mAb / ml serum; in vivo: BALB/c mice 40 mg mAb/kg/day, 0-2 days followed by twice a week.
IA: Wells were coated with 2-4 µg purified BB5.1 in PBS as coat antibody for use in ELISA.
IP: Mouse serum was pre-adsorbed with αmouse-Ig affinity gel and prot-A-sepharose for 30 min at RT. Then C5 was precipitated with BB5.1 (10 µg mAb/ml followed by prot-A sepharose for 1h). Precipitated samples were analysed on 7% SDS/PAGE.
|Use||Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.|
|Cross reactivity||Rat - Yes|
|Alias||Complement C5, Hemolytic complement Gene name: C5|
|References||1. Frei, Y et al; Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol Cell Probes 1987, 1: 141 2. Thurman, J et al; C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ischemia/reperfusion. J Immunol 2007, 178: 1819 3. Mihai, S et al; The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol 2007, 178: 6514 4. Wang, H et al; Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007, 179: 4451 5. Huugen, D et al; Inhibition of complement factor C5 protects against antimyeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007, 71: 646 6. Nilsson, K et al. Enhanced susceptibility to low-dose collagen-induced arthritis in CR1/2-deficient female mice – possible role of estrogen on CR1 expression. Faseb 2009, 23: 2450 7. Copland, D et al. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clin exp immunol 2010, 159:303 8. Pavlovski, D et al; Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis, Faseb 2012, 26: 3680|
|Storage and stability||Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.|
|Precautions||For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use or derivation of this product.|
|Disease||Infectious diseases, Nephrology|